39.43
Tg Therapeutics Inc stock is traded at $39.43, with a volume of 3.78M.
It is down -1.08% in the last 24 hours and up +31.04% over the past month.
See More
Previous Close:
$39.86
Open:
$38.32
24h Volume:
3.78M
Relative Volume:
1.57
Market Cap:
$4.54B
Revenue:
$264.79M
Net Income/Loss:
$-14.36M
P/E Ratio:
-358.45
EPS:
-0.11
Net Cash Flow:
$-28.11M
1W Performance:
-7.46%
1M Performance:
+31.04%
6M Performance:
+68.58%
1Y Performance:
+159.24%
Tg Therapeutics Inc Stock (TGTX) Company Profile
Name
Tg Therapeutics Inc
Sector
Industry
Phone
(212) 554-4484
Address
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY
Compare TGTX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
TGTX
Tg Therapeutics Inc
|
39.43 | 4.54B | 264.79M | -14.36M | -28.11M | -0.11 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Tg Therapeutics Inc Stock (TGTX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Oct-29-24 | Initiated | TD Cowen | Buy |
Aug-02-23 | Upgrade | Goldman | Sell → Neutral |
Jun-26-23 | Resumed | Jefferies | Buy |
May-20-22 | Initiated | BofA Securities | Underperform |
Feb-23-22 | Reiterated | B. Riley Securities | Buy |
Nov-15-21 | Downgrade | Goldman | Neutral → Sell |
Apr-20-21 | Initiated | Goldman | Neutral |
Apr-19-21 | Reiterated | H.C. Wainwright | Buy |
Sep-01-20 | Initiated | JP Morgan | Overweight |
Aug-11-20 | Reiterated | H.C. Wainwright | Buy |
Jun-05-20 | Initiated | Evercore ISI | Outperform |
Jan-17-20 | Reiterated | H.C. Wainwright | Buy |
Nov-27-19 | Resumed | B. Riley FBR | Buy |
Feb-06-19 | Resumed | Jefferies | Buy |
Sep-25-18 | Downgrade | Raymond James | Strong Buy → Outperform |
Mar-09-18 | Reiterated | B. Riley FBR, Inc. | Buy |
Dec-01-17 | Resumed | B. Riley FBR, Inc. | Buy |
Nov-14-17 | Resumed | H.C. Wainwright | Buy |
Apr-25-17 | Initiated | Jefferies | Buy |
Mar-06-17 | Reiterated | FBR & Co. | Outperform |
Oct-06-16 | Resumed | Brean Capital | Buy |
May-27-16 | Initiated | SunTrust | Buy |
Dec-01-15 | Initiated | FBR Capital | Outperform |
Sep-09-15 | Initiated | Raymond James | Strong Buy |
Aug-12-15 | Resumed | H.C. Wainwright | Buy |
Jun-19-15 | Reiterated | Brean Capital | Buy |
Dec-11-14 | Reiterated | ROTH Capital | Buy |
Dec-10-14 | Reiterated | ROTH Capital | Buy |
View All
Tg Therapeutics Inc Stock (TGTX) Latest News
Should We Be Cautious About TG Therapeutics, Inc.'s (NASDAQ:TGTX) ROE Of 11%? - Yahoo Finance
Strength Seen in TG Therapeutics (TGTX): Can Its 10.2% Jump Turn into More Strength? - MSN
Based On Its ROE, Is TG Therapeutics, Inc. (NASDAQ:TGTX) A High Quality Stock? - simplywall.st
(TGTX) Investment Analysis and Advice - Stock Traders Daily
TG Therapeutics stock soars to 52-week high of $43.03 By Investing.com - Investing.com South Africa
TG Therapeutics stock soars to 52-week high of $43.03 - Investing.com India
TG Therapeutics (TGTX) technical analysisTG Therapeutics (NASDAQ:TGTX) - Benzinga
TG Therapeutics (TGTX): Among the Best Short Squeeze Stocks to Buy According to Analysts - Yahoo Finance
Multiple Sclerosis Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Medication, Epidemiology, Prevalence, Therapies and Companies by DelveInsight - The Globe and Mail
Precision & TG Therapeutics: Unlocking Value With ARCUS, BRIUMVI And Azer-Cel (NASDAQ:DTIL) - Seeking Alpha
TG Therapeutics stock soars to 52-week high of $40.32 By Investing.com - Investing.com Australia
TG Therapeutics: Bright Outlook, Bolstered By Briumvi And Upcoming Trials (NASDAQ:TGTX) - Seeking Alpha
TG Therapeutics stock soars to 52-week high of $40.32 - Investing.com India
TG Therapeutics Stock (TGTX): Advancing MS Treatment - Value The Markets
Is TG Therapeutics, Inc. (TGTX) the Best Performing Growth Stock in 2025? - Insider Monkey
(TGTX) Technical Data - Stock Traders Daily
TG Therapeutics: Exciting Briumvi Performance, Looking To Re-Enter (NASDAQ:TGTX) - Seeking Alpha
10 Best Performing Growth Stocks in 2025 - Insider Monkey
Proficio Capital Partners LLC Buys Shares of 10,174 TG Therapeutics, Inc. (NASDAQ:TGTX) - Defense World
TG Therapeutics call volume above normal and directionally bullish - TipRanks
Smartleaf Asset Management LLC Has $60,000 Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) - Defense World
TG Therapeutics (NasdaqCM:TGTX) Surges 28% Following US$23 Million Net Income Turnaround - Yahoo Finance
Bilibili, MARA And ZEEKR Are Among Top 8 Mid-Cap Gainers Last Week (Mar 3-Mar 7): Are The Others In Your Portfolio? - Benzinga
Bank of New York Mellon Corp Increases Stake in TG Therapeutics, Inc. (NASDAQ:TGTX) - Defense World
Q2 Earnings Forecast for TG Therapeutics Issued By B. Riley - Defense World
Why TG Therapeutics Stock Was Soaring This Week - MSN
TGTX Surges on Strong Q4 Results and Briumvi Success - GuruFocus.com
Why TG Therapeutics Shares Are Soaring Now - TipRanks
Retail Bets TG Therapeutics Stock Can Sustain Post-Earnings Gains Throughout The Week - MSN
TG Therapeutics Announces Schedule of Data Presentations - GlobeNewswire
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting - Yahoo Finance
Q1 Earnings Forecast for TG Therapeutics Issued By B. Riley - Defense World
This Biotech Stock Hits Buy Point After Earnings Burst - MSN
HC Wainwright Reaffirms “Buy” Rating for TG Therapeutics (NASDAQ:TGTX) - Defense World
TG Therapeutics FY2025 EPS Estimate Boosted by HC Wainwright - Defense World
Why TG Therapeutics, Inc. (TGTX) Surged On Monday? - MSN
TG Therapeutics, Inc. (NASDAQ:TGTX) Holdings Decreased by Private Advisor Group LLC - Defense World
TG Therapeutics (NASDAQ:TGTX) Upgraded by StockNews.com to Hold Rating - Defense World
TG Therapeutics (NASDAQ:TGTX) Shares Up 5.2% After Earnings Beat - Defense World
TG Therapeutics, Inc. (NASDAQ:TGTX) Q4 2024 Earnings Call Transcript - MSN
TG Therapeutics Target of Unusually Large Options Trading (NASDAQ:TGTX) - Defense World
TG Therapeutics, A New Leaderboard Stock, Skyrockets 17% On Sales Beat, Bullish Guide - MSN
TG Therapeutics stock soars to 52-week high of $36.89 By Investing.com - Investing.com South Africa
TG Therapeutics stock soars to 52-week high of $36.89 - Investing.com India
Cautious Outlook on TG Therapeutics Amid Competitive Pressures and Overvaluation Concerns - TipRanks
B. Riley Raises Price Target on TG Therapeutics to $53 From $38, Keeps Buy Rating -March 04, 2025 at 08:05 am EST - Marketscreener.com
Tg Therapeutics Inc Stock (TGTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):